Pfizer, the maker of Celontin (methsuximide) have informed the Epilepsy Foundation that there will likely be a shortage of the medication starting in early August and lasting through September. Generic substitute for this medication is not available.
Celontin is a medication that is not in common use. It is primarily used to treat a seizure type called absence. This seizure type usually begins in childhood. Often, Celontin is used when other medicines fail to control seizures. The Epilepsy Foundation is dedicated to keeping people with epilepsy safe. We would like to provide some general information to help people avoid any serious health consequences of the Celontin shortage. |
|
If you have an interruption or reduction in your Celontin regimen, even if it is brief, breakthrough seizures may be possible, even if you have been seizure free for some time. Therefore, you should not drive, operate heavy machinery or engage in other activities that would put at risk should a seizure occur, until you are back on your regular medication regimen. |
Medication Recall Alert Sabril® (Vigabatrin)
Our friends at the Epielpsy Foundation have shared the Following Medication Recall The company that makes Sabril® (vigabatrin) for oral solution, a prescription medication to manage seizures in children and adults, has announced a recall of this medication because of...